KindlyMD (NASDAQ:NAKA – Get Free Report) announced its earnings results on Thursday. The company reported ($6.65) EPS for the quarter, FiscalAI reports. The company had revenue of $35.87 million during the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%.
KindlyMD Stock Up 2.2%
NASDAQ:NAKA traded up $0.11 on Thursday, reaching $5.05. 118,522 shares of the company’s stock traded hands, compared to its average volume of 196,532. The stock has a 50-day simple moving average of $4.37 and a 200-day simple moving average of $7.65. KindlyMD has a 12 month low of $3.33 and a 12 month high of $624.00. The firm has a market cap of $87.88 million, a PE ratio of -0.12 and a beta of 15.95.
Wall Street Analysts Forecast Growth
A number of analysts have commented on NAKA shares. TD Cowen upped their price target on KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $22.33.
Insider Buying and Selling at KindlyMD
In other KindlyMD news, CEO David F. Bailey bought 104,833 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was purchased at an average price of $4.84 per share, for a total transaction of $507,391.72. Following the completion of the transaction, the chief executive officer owned 3,120,361 shares of the company’s stock, valued at $15,102,547.24. This trade represents a 3.48% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders bought a total of 191,448 shares of company stock valued at $992,908 over the last three months. Corporate insiders own 24.49% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. purchased a new stake in KindlyMD during the 2nd quarter valued at approximately $215,000. Geode Capital Management LLC lifted its holdings in shares of KindlyMD by 76.2% in the second quarter. Geode Capital Management LLC now owns 19,394 shares of the company’s stock worth $484,000 after buying an additional 8,386 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of KindlyMD by 1,638.4% in the third quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company’s stock worth $827,000 after buying an additional 31,245 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of KindlyMD during the third quarter worth $1,007,000. Finally, Vident Advisory LLC bought a new position in shares of KindlyMD during the third quarter worth $2,092,000.
KindlyMD Company Profile
Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.
Featured Stories
- Five stocks we like better than KindlyMD
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for KindlyMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KindlyMD and related companies with MarketBeat.com's FREE daily email newsletter.
